齐拉西酮与奥氮平治疗首发精神分裂症对照研究

目的：探讨齐拉西酮与奥氮平治疗首发精神分裂症的临床疗效与安全性。方法：将64例首发精神分裂症患者随机分为齐拉西酮组32例与奥氮平组32例,治疗8周。采用阳性与阴性症状量表（PANSS）评定疗效,采用治疗中出现的症状量表（TESS）评定不良反应。结果：齐拉西酮组总有效率为84.4%,奥氮平组为87.5%,两组差异无显著性（P〉0.05）。齐拉西酮组主要不良反应是失眠,奥氮平组是体质量增加和血糖升高。结论：齐拉西酮与奥氮平治疗首发精神分裂症均有良好疗效,2药不良反应均较轻。

Comparing ziprasidone and olanzapine in treatment of schizophrenia

Objective: To compare the efficacy and safety of ziprasidone and olanzapine in the treatment of first-episode schizophrenia. Method:Sixty-four patients with schizophrenia were randomly allocated to ziprasidone group(n=32) or olanzapine group(n=32) respectively,and the duration of treatment was 8 weeks.The positive and negative syndrome scale(PANSS) and treatment emergent side effect scale(TESS) were used to evaluate the efficacy and adverse effects. Results:The efficacy rates of ziprasidone and olanzapine were 84.4% and 87.5% respectively after 8 week's treatment.There was no significant difference in the efficacy rates between the two groups (P>0.05).The side effects of ziprasidone were insomnia,and those of olanzapine were increased weight and blood glucose levels. Conclusion: Ziprasidone is as effective and safe as olanzapine for the treatment of first-episode schizophrenia,and with fewer side effects.